MK-677 Supplement Linked to Reversible Liver Damage in Healthy Man
Background
MK-677, a growth hormone secretagogue, is increasingly popular as a performance-enhancing supplement due to its anabolic effects. While commonly associated with side effects like oedema, increased appetite, and muscle pain, reports of hepatotoxicity (liver damage) have been remarkably scarce. This case report addresses the critical gap in understanding the potential for MK-677 to induce liver injury in otherwise healthy individuals.
Results
The primary finding was the development of transaminitis, indicated by significantly elevated liver enzyme levels, in the patient after 2 months of MK-677 use. These elevated enzymes are a clear biomarker for acute liver injury. The patient's liver health deteriorated while on the supplement, showing a direct correlation with its use. > The most critical observation was that after the patient discontinued MK-677 supplementation, his liver function tests (LFTs) eventually returned to normal limits, directly implicating the compound as the cause of the hepatotoxicity. This rapid normalization of LFTs upon cessation strongly suggests a direct causal link between MK-677 and the observed liver damage, rather than an underlying chronic condition. The patient's liver health improved completely without further medical intervention once the supplement was stopped, demonstrating the reversibility of the injury.
Why It Matters
This case report highlights a critical, under-recognized risk associated with MK-677 use, particularly given its widespread availability and popularity in the performance-enhancing supplement market. It underscores the importance for healthcare professionals to consider drug-induced liver injury (DILI) when evaluating patients presenting with unexplained transaminitis, especially those with a history of supplement use. The findings suggest that MK-677 should be considered a potential cause of hepatotoxicity, warranting increased vigilance and potentially leading to more cautious recommendations for its use. Further research, including larger cohort studies or controlled clinical trials, is needed to fully characterize the incidence and mechanisms of MK-677-induced liver injury.